Research feed
Recently published diabetes studies added to Dediabetes, summarized and organized by intervention and outcome.
Sorted by publication date. Some studies may have been added to Dediabetes later.
The study investigated the effects of adding Empagliflozin to standard treatment in patients with Type 2 Diabetes, finding significant reductions in hepatic fat mass and BMI.
This study evaluated the impact of metronidazole as an adjunct to scaling and root planing on insulin resistance in type 2 diabetes patients with periodontitis, finding significant changes in HOMA-IR at 6 months.
This study evaluated the safety and potential therapeutic effects of orally delivered insulin in patients with metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus, finding significant reductions in liver fat and fibrosis levels.
This study investigated the effects of Vildagliptin and Metformin on hepatic steatosis in newly diagnosed Type 2 diabetes patients, showing significant improvements in various metabolic parameters.
This study evaluated the efficacy and safety of dapagliflozin in participants with metabolic dysfunction-associated steatohepatitis (MASH), finding significant improvements in liver health outcomes.
This study investigated the impact of ozone therapy on glycated hemoglobin levels in type 2 diabetes patients, finding no significant reduction in HbA1c levels.
This study investigated the efficacy of pioglitazone in treating NAFLD patients with abnormal glucose metabolism, revealing significant liver fat content reduction in women compared to men.
This study evaluated the effectiveness of probiotics and tetracycline fibers as adjuncts to scaling and root planing in type 2 diabetic patients with periodontitis, finding significant reductions in inflammatory markers and periodontal indices.
This study compared the effects of Saroglitazar and Pioglitazone on liver health and blood sugar control in patients with Type 2 Diabetes and liver disease, finding significant improvements in certain measures.
This study evaluated the combination therapy of Tofogliflozin and Pioglitazone for treating hepatic steatosis in patients with NAFLD and T2DM, showing significant improvements in various metabolic parameters.
Latest Evidence
Build your workspace to keep track of the latest diabetes research.
